Viewing data from:

SPRAVATO

NDA

ESKETAMINE HYDROCHLORIDE | N211243 | JANSSEN PHARMACEUTICALS INC

1 strength7 unique patents1 unique exclusivity

Patent Timeline

7 unique patents, 1 exclusivity by expiration date

Expiring < 1yr (1)Active (6)TodayExclusivity

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

Today

Mar. 5, 2033

Mar. 20, 2027

Sep. 10, 2035

Sep. 10, 2035

Sep. 10, 2035

Mar. 14, 2034

Feb. 18, 2040

I-959

Jan. 17, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

1 case on OB patents (1 active) from PACER

Case	Court	Filed	Status	Judge
JANSSEN PHARMACEUTICALS, INC. et al v. ALKEM LABORATORIES LTD. et al 1:2023cv02939 4 patentsANDA 218468esketamine	D.N.J.	2023-05-30	Active	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Spravato (2023)

Total Spending

$80.5M

Total Claims

56,477

Beneficiaries

3,884

Avg Cost/Unit

$382.22

Spending Trend

$7.6M(2019)→$21.8M(2020)→$32.9M(2021)→$50.0M(2022)→$80.5M(2023)

YoY Change:+7.6%

5yr CAGR:+5.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs

5 active API suppliers hold Drug Master Files for this ingredient.

SUPRIYA LIFESCIENCE LTDESKETAMINE HYDROCHLORIDE

DMF 364262021

AREVIPHARMA GMBHESKETAMINE HYDROCHLORIDE

DMF 369902022

MAITHRI DRUGS PRIVATE LTDESKETAMINE HYDROCHLORIDE

DMF 370122022

ALKEM LABORATORIES LTDESKETAMINE HYDROCHLORIDE

DMF 374612022

NORTEC QUIMICA SAESKETAMINE HYDROCHLORIDE

DMF 376472022

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

18 letters from Drugs@FDA

Date	Submission	Document
Jun 26, 2026	SUPPL -29	View Letter (PDF)
Apr 21, 2026	SUPPL -28	View Letter (PDF)
Jan 26, 2026	SUPPL -27	View Letter (PDF)
Oct 10, 2025	SUPPL -25	View Letter (PDF)
Aug 1, 2025	SUPPL -24	View Letter (PDF)
May 19, 2025	SUPPL -21	View Letter (PDF)
May 1, 2025	SUPPL -19	View Letter (PDF)
Mar 28, 2025	SUPPL -18	View Letter (PDF)
Feb 4, 2025	SUPPL -16	View Letter (PDF)
Jan 2, 2025	SUPPL -13	View Letter (PDF)
Nov 5, 2024	SUPPL -15	View Letter (PDF)
Oct 19, 2023	SUPPL -12	View Letter (PDF)
Jan 5, 2022	SUPPL -6	View Letter (PDF)
Aug 3, 2020	SUPPL -4	View Letter (PDF)
Feb 12, 2020	SUPPL -3	View Letter (PDF)
Jun 26, 2019	SUPPL -2	View Letter (PDF)
May 13, 2019	SUPPL -1	View Letter (PDF)
Mar 6, 2019	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 28MG BASE

RLD

7 patents1 exclusivity▴

SPRAY;NASAL | Approved: Mar 5, 2019

Patents (7)

Patent #	Expiration	PED	Drug Substance	Drug Product	Delist
8785500	Mar 5, 2033	—	—	—	—
9592207	Mar 20, 2027	—	—	—	—
10869844	Sep 10, 2035	—	—	—	—
11173134	Sep 10, 2035	—	—	—	—
11311500	Sep 10, 2035	—	—	—	—
11446260	Mar 14, 2034	—	—	—	—
11883526	Feb 18, 2040	—	—	—	—

Exclusivities (1)

Code	Date	Status
I-959	Jan 17, 2028	Active